Gerresheimer AG (GRRMF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Gerresheimer Ag.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.330 -- 00:00:06.152 Thank you, operator. First of all, I would like to impress a thank you, a very big thank 00:00:06.152 -- 00:00:09.133 you for your continuous support of Becker Refrainer. 00:00:09.133 -- 00:00:14.196 We have not had an earnings call for quite some time that we fully focused on 00:00:14.196 -- 00:00:19.438 completing our investigations and ensuring clean, robust, and especially 00:00:19.438 -- 00:00:23.000 compliant set of 2025 financials. 00:00:23.000 -- 00:00:28.302 This was accomplished today and we were able to publish our audited 2025 00:00:28.302 -- 00:00:30.043 annual report. 00:00:30.043 -- 00:00:35.736 Our management board will explain our results in more detail. 00:00:36.038 -- 00:00:40.763 First on the disclaimer. Please let me remind you that the disclaimer you can find in 00:00:40.763 -- 00:00:46.089 our full year 2025 slide deck will apply throughout this earnings call 00:00:46.089 -- 00:00:49.832 and we assume your consent to this. 00:00:49.832 -- 00:00:54.222 I will therefore not read it out loud. Please allow me some selected clarification. 00:00:54.222 -- 00:00:58.185 Due to rounding, numbers presented throughout this report may not add up precisely to 00:00:58.185 -- 00:01:03.309 the totals indicated and percentages may not precisely reflect the absolute figures 00:01:03.309 -- 00:01:05.030 for the same. 00:01:05.030 -- 00:01:10.394 Organic revenue and organic adjusted EVGA include the revenues and adjusted EVGA 00:01:10.394 -- 00:01:15.738 of Bormioli Pharma in both 2024 and 2025, which we acquired in December 00:01:15.738 -- 00:01:22.401 10, 2024 and fully consolidate from the beginning of the financial year 2025. 00:01:22.421 -- 00:01:27.863 Translated at the budgeted exchange rates for the financial year 2025....